-
Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development
Tuesday, May 12, 2020 - 2:08pm | 754Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results. The Novavax Analysts H.C. Wainwright analyst Vernon Bernardino reiterated a Buy...
-
Analyst: Entrectinib's Potential Gives Ignyta's Stock 116% Upside
Wednesday, October 18, 2017 - 11:23am | 327Analysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc (NASDAQ: RXDX) after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2...
-
What Do Versartis' Troubles Mean For Opko Health?
Friday, September 22, 2017 - 11:26am | 597Versartis Inc (NASDAQ: VSAR) shares are slumping even as rival Opko Health Inc. (NASDAQ: OPK) is seeing slight strength, though not proportionate to the sell-off seen in Versartis shares. News Behind The Move Versartis announced Thursday after the market close that its Somavaratan, a long-...
-
Meet VBI Vaccines, The Biotech Up 100% In 2017
Tuesday, March 7, 2017 - 1:30pm | 582If you've been too distracted by the Snap Inc (NYSE: SNAP) IPO lottery ticket trade to keep your eye on small-cap biotech moves, you may not have noticed VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV) shares quietly doubling in value since the start of the year. VBI Vaccines is a...
-
Is There Still A Path Forward For The Novovax RSV Vaccine?
Tuesday, February 28, 2017 - 11:17am | 396“While we continue to believe Novavax, Inc. (NASDAQ: NVAX) has an active vaccine for the prevention of RSV (Respiratory syncytial virus), we view a Neutral rating as appropriate given limited visibility on optimal dose/schedule for future development in an elderly population and modest...
-
Myriad Genetics' Sell Thesis Is 'Largely Played Out'
Wednesday, February 8, 2017 - 10:33am | 436Ladenburg Thalmann upgraded shares of Myriad Genetics, Inc. (NASDAQ: MYGN), premised on valuation, as it views that the sell thesis has largely played out. Q2 Largely In Line Analyst Kevin DeGeeter noted that the company reported second-quarter non-GAAP earnings of $0.26 per share on revenues...
-
Opko Health's 18% Selloff Offers Buying Opportunity
Tuesday, January 3, 2017 - 9:12am | 303Shares of Opko Health Inc. (NASDAQ: OPK) slumped after the release of mixed results from a Phase III clinical study of long-acting human growth hormone [hGH-CTP] candidate in adults with growth hormone deficiency. “We view the sell off as overblown and an opportunity to acquire shares,...
-
Ladenburg Downgrades Cempra Following FDA's Complete Response Letter
Thursday, December 29, 2016 - 3:41pm | 372Ladenburg Thalmann has downgraded Cempra Inc (NASDAQ: CEMP) to Neutral from Buy following the complete response letter from the FDA for Solithromycin for treatment of Community Acquired Bacterial Pneumonia (CABP). The letter cites both manufacturing deficiencies at contract manufacturer Wockhardt...
-
Kindred Biosciences Is 'Setting The Pace In Animal Health Biologics'
Tuesday, November 1, 2016 - 11:25am | 295Ladenburg Thalmann’s Kevin DeGeeter believes Kindred Biosciences Inc (NASDAQ: KIN) has an attractive growth opportunity in biologic therapies for the treatment of companion animals. DeGeeter initiated coverage of the company with a Buy rating and price target of $7.50. Setting The Pace...
-
Ladenburg Initiates BioTime Shares With Buy, $6 Price Target
Friday, September 23, 2016 - 8:59am | 306BioTime, Inc. (NYSEMKT: BTX) is in the midst of a restructuring that is aimed at unlocking shareholder value by separating non-core assets and the accelerated development of cell therapy programs in ophthalmetry, aesthetics and orthopedics, Ladenburg’s Kevin DeGeeter said in a report. He...
-
Ladenburg Says No Need For Novavax To Rerun Failed Drug Study
Friday, September 16, 2016 - 8:57am | 338Top-line Phase III data for Novavax, Inc’s (NASDAQ: NVAX) RSV F nanoparticle vaccine for the prevention of RSV in the elderly was disappointing, Ladenburg’s Kevin DeGeeter said in a report. He downgraded the rating on the company from Buy to Neutral, and removed the price target....
-
Sequenom Can't Go Back; Ladenburg Analysts Downgrade To Sell
Tuesday, September 29, 2015 - 4:29pm | 396Shares of Sequenom, Inc. (NASDAQ: SQNM) are down roughly 13 percent on Tuesday trading, following the company's investor day event on Monday. Following the gathering, analysts at Ladenburg Thalmann downgraded shares of the company from Neutral to Sell, setting a $0.90 price target. According to a...
-
The Wall Street Research Making Waves Today
Friday, July 31, 2015 - 12:22pm | 1376The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." JPMorgan: Downgrading Linn Energy Gabriel Daoud of JPMorgan downgraded shares of both Linn Energy LLC (NASDAQ: LINE) and LinnCo LLC (NASDAQ:...